Love DermNet?

Subscribe to our monthly newsletter.

Key clinical-trial evidence for interferon for melanoma

Author: Anoma Ranaweera B.V. Sc; PhD (Clinical Biochemistry, University of Liverpool, UK). Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, December 2015.

Three types of interferon-alpha are commercially available: peginterferon alfa-2b (Sylatron®; Schering-Plough Corporation, Madison New Jersey [NJ], USA), interferon alfa-2b (Intron® A; Schering-Plough Corporation, Madison NJ , USA), and interferon alfa-2a (Roferon&reg-A;, Hoffmann-La Roche, Madison, NJ, USA); each differs minimally in their amino-acid sequence.

All preparations are available in New Zealand except peginterferon alfa-2b.

Peginterferon alfa-2b (Sylatron®)

Peginterferon. Drug-related adverse reactions in >5% of patients
Sylatron® (n = 629) Observation (n = 628)
Adverse reaction All grades (%) All Grades (%)
General disorders and administration site conditions
Fatigue 94 41
Pyrexia 75 9
Chills 63 6
Injection site reactions 62 0
Gastrointestinal disorders
Diarrhoea 37 8
Nausea 64 11
Vomiting 26 4
Respiratory disorders
Dyspnoea 6 2
Cough 5 2
Skin disorders
Rash 36 4
alopecia 34 1
Musculoskeletal disorders
Arthralgia 51 22
Myalgia 68 23
Nervous system disorders
Headache 70 19
Dizziness 35 11
Liver function
Increased AST 77 26

Interferon alfa-2b (Intron®A)

ECOG 1684

ECOG 1690

Interferon alfa-2a (Roferon® -A)

French Melanoma Cooperative Group Trial

Austrian Melanoma Cooperative Group Trial

Future directions

Related information

Make a donation

Donate Today

Help us to update and maintain DermNet New Zealand

Submit your images

We are expanding our image library

Contact us

Skin lesion photography

Watch Dr Amanda Oakley presenting "Skin lesion photography" at The Australasian Skin Cancer Congress.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter